On the 14th of january 2013, the APC-PCI patent will be settled.
The EPO has summoned for oral proceedings, as they declare that the present application is missing a vital piece.
EPO declares that since the application is missing a crucial cut-off value, it is as such useless.
Bioporto on the other hand finds the application to be fulfilling all the relevant rules.
The oral proceedings will settle this dispute, and will decide if Bioporto will hold its first US/EU patent, or if they will have to settle on holding the US patent on the use of APC-PCI as a marker for the selection of patients with severe sepsis.
Read the decision on why EPO calls for a summon.
Så er Oral proceedings aflyst efter telefonsamtalen den 26/11, hvilket vil sige at Bioporto formentlig står med det første EPO/USPTO patent inden længe.
Jamen så kan vi jo sige goddag til Eli Lilly igen….